<i>In vivo</i> Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial.

In the REDUC trial, the viral inhibition assay showed a trend toward increased inhibitory activity post-immunization that was lost after RMD exposure, but overall, antiviral capacity did not significantly change over time.

also in 53,322 other papers

The immune analyses in BCN02 showed a highly significant shift of HIV-1-specific T-cell responses toward conserved regions of HIV-1 covered by the immunogen and marked increases in histone acetylation and induction of viral transcription in vivo by RMD.

also in 132,142 other papers